English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The ƒÁ-Seminoprotein (ƒÁ-Sm) and the Prostatic Acid Phosphatase (PAP) have recently been studied as useful tumor markers for prostatic cancer. Both PAP and ƒÁ-Sm in patients with prostatic cancer have been assayed and the data relevant to the usefulness of ƒÁ-Sm as well as PAP have been analyzed. The results obtained are as follows. A total of 89 cases with prostatic cancer, Benign Prostatic Hypertrophy (BPH), prostatitis and other urological diseases were the subjects of this study. The number of samples tested was 233 for ƒÁ-Sm and 229 for PAP. The patients with prostatic cancer who were definitely diagnosed histopathologically and whose disease stages were classified were used primarily, and blood samples were collected from these patients. PAP was assayed by the RI method, and ƒÁ-Sm by the EIA method. According to previous clinical reports, the cut off value for ƒÁ-Sm was set at 4.0ng/ml. The level of ƒÁ-Sm observed was 3.9ng/ml in patients with BPH, 1.9ng/ml in those with prostatitis, 1.ing/ml in cases with other cancers of the urinary organs, 11.0ng/ml in patients with untreated

A comparative evaluation of PAP and .GAMMA.-Sm as the tumor markers of prostatic cancer.